HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy.

@article{Miller2000HIV1RT,
  title={HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy.},
  author={Veronica Miller and Mounir Ait-Khaled and Chris Stone and Philip A. Griffin and D Mesogiti and Amy G Cutrell and Richard Harrigan and Schlomo Staszewski and Christine Katlama and Gill Pearce and Margaret Tisdale},
  journal={AIDS},
  year={2000},
  volume={14 2},
  pages={163-71}
}
OBJECTIVE To examine changes in HIV-1 susceptibility (genotype and phenotype) during an initial abacavir monotherapy phase followed by the addition of zidovudine and lamivudine. DESIGN Sixty HIV-1 infected, antiretroviral therapy-naive subjects were randomized to receive 100, 300 or 600 mg abacavir twice daily. Subjects completing 24 weeks of randomized therapy or meeting a protocol defined switch criterion could switch to open label abacavir/zidovudine/lamivudine. METHODS Plasma HIV-1… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 36 extracted citations

Similar Papers

Loading similar papers…